12 news items
HC Wainwright & Co. Reiterates Buy on Day One Biopharmaceutical, Maintains $40 Price Target
DAWN
20 Jun 24
HC Wainwright & Co. analyst Andres Maldonado reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $40 price target.
Needham Reiterates Buy on Day One Biopharmaceutical, Maintains $33 Price Target
DAWN
19 Jun 24
Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
DAWN
18 Jun 24
Targets PTK7, highly expressed in broad range of adult and pediatric solid tumors BRISBANE, Calif., June 18, 2024 (GLOBE
Day One Announces Sale of Priority Review Voucher for $108 Million
DAWN
30 May 24
" or the "Company"), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages
HC Wainwright & Co. Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $40
DAWN
7 May 24
HC Wainwright & Co. analyst Andres Maldonado maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the price target from $50 to $40.
8yzb3sqqr942231ypn83q9qes1rvvqdx9z3efu0hcmayczy84oro
DAWN
7 May 24
Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.
hu7ak9lrmt7hvlukzt0vckn3tnkax63yms5f0lvq
DAWN
6 May 24
biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its
gmdncs4g72mffl yy
DAWN
25 Apr 24
Needham analyst Ami Fadia reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $33 price target.
6zj fugedacyx62bp520rjwnpb1m
DAWN
24 Apr 24
HC Wainwright & Co. analyst Andres Maldonado reiterates Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and maintains $50 price target.
ccadfccubyvm 3w47ppeyorjccgjrll5j
DAWN
24 Apr 24
Needham analyst Ami Fadia maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and raises the price target from $30 to $33.
3clsu04
DAWN
23 Apr 24
and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration
x8d33lxdswt9w3g1h2r0z91dckl3dpnmtkez1p2tj9mg7mtaob2
DAWN
22 Apr 24
JP Morgan analyst Anupam Rama maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and raises the price target from $32 to $36.
- Prev
- 1
- Next